Highlights
- Heart-sparing radiotherapy significantly reduces cardiac morbidity, but dose to the left anterior descending artery (LAD) is a superior predictor of long-term cardiac events compared to mean whole-heart dose.
- Modern radiotherapy techniques, including 3D-conformal and intensity-modulated radiation therapy with respiratory motion management, optimize LAD dose sparing.
- Longitudinal clinical data reveal a dose threshold of approximately 12 Gy EQD2 to the LAD beyond which cardiac risk markedly increases.
- Subclinical cardiac dysfunction detected by advanced imaging correlates with cardiac doses and can inform early cardioprotective interventions.
Background
Breast cancer remains one of the most prevalent malignancies worldwide, and advancements in adjuvant therapies, particularly radiotherapy, have substantially improved survival rates. However, incidental cardiac radiation exposure, especially in left-sided breast cancer, raises concerns for radiation-induced heart disease (RIHD), manifesting years after treatment completion as ischemic heart disease, arrhythmias, valvular dysfunction, and heart failure. Historically, mean heart dose (MHD) has been the principal dosimetric parameter used to estimate cardiac risk post-radiotherapy. Yet, recent evidence challenges this by implicating the dose to cardiac substructures, notably the left anterior descending coronary artery (LAD), as a more accurate predictor of late cardiac events. The clinical imperative is to refine radiotherapy planning to minimize cardiac toxicity without compromising oncologic outcomes.
Key Content
1. Dose-Dependent Cardiac Risks and Limitations of Whole-Heart Metrics
Meta-analyses (Zhang et al., Heart, 2025; PMID 40348406) encompassing over 600,000 patients have demonstrated a clear linear association between cardiac radiation dose and subsequent cardiovascular morbidity. Left-sided radiotherapy confers higher cardiac event risk than right-sided irradiation, attributable to proximity of the heart, especially coronary arteries, to radiation fields. Importantly, studies reveal that the MHD, while predictive of risk, may inadequately represent the highest dose to critical cardiac substructures.
In randomized and observational studies (KROG 15-03, 2025; PMID 40345828), the incidence of major cardiac events (MCEs) increased by approximately 21% per 1-Gy increase in MHD during the first 6.5 years post-treatment. However, the precision of MHD as a risk estimator is limited by patient anatomy and heterogeneous dose distribution across cardiac tissues.
2. Superior Predictive Ability of LAD Radiation Dose
The pivotal cross-sectional Canadian study by Quirk et al. (JAMA Oncology, 2026; PMID 42390858) involving 4908 patients, including 2223 with left-sided breast cancer, established that maximum LAD dose (expressed in EQD2) better discriminated cardiac risk than mean heart dose. Using advanced automated LAD segmentation, a data-driven LAD dose cut-off of 12 Gy EQD2 was identified, above which cardiac events significantly increased (subdistribution hazard ratio 1.81, P = .04). This suggests that even when mean heart dose remains low, focal high doses to the LAD are deleterious.
Additional studies (Guthier et al., Phys Med, 2024; PMID 39504787) emphasize the clinical challenge that LAD anatomy variability and cardiac motion impose on accurate dose estimation, advocating for consistent contouring protocols and safety margins (a 10 mm delineation margin around LAD is suggested) to improve dose reporting and risk stratification.
3. Advances in Radiotherapy Techniques to Minimize Cardiac Dose
Modern radiotherapy techniques, including 3D conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), and proton therapy, offer improved conformality to reduce cardiac exposure. Respiratory motion management, especially deep inspiration breath hold (DIBH), has been shown to effectively reduce radiation dose to the heart and LAD by increasing the distance between the heart and chest wall during irradiation (Radiography, 2025; PMID 39779416).
Meta-analyses comparing thoracic versus abdominal DIBH techniques demonstrate that abdominal breath hold may further decrease LAD dose, though mean heart dose differences are less pronounced. Patient coaching and standardization of breath-hold training are critical to realize these benefits consistently.
4. Subclinical Cardiac Dysfunction and Biomarkers Post-Radiotherapy
Cardiac MRI studies (MEDIRAD EARLY-HEART, Radiol Cardiothorac Imaging, 2025; PMID 40178396) reveal modest but persistent reductions in left ventricular global longitudinal strain (GLS) associated with higher whole heart and left ventricular doses over two years post-radiotherapy. These subclinical dysfunctions precede overt cardiac events, underscoring the importance of early detection.
Furthermore, phase 2 trials integrating cardiac MRI with serum biomarkers (troponin I, IL-6) show potential correlations with radiation dose and emerging cardiotoxicity (Int J Radiat Oncol Biol Phys, 2022; PMID 34509552), highlighting avenues for personalized cardioprotection.
5. Cardioprotective Strategies and Clinical Outcomes
Randomized trials (SAFE trial substudy, Echocardiography, 2025; PMID 40965835) demonstrate that neurohormonal blockade (bisoprolol, ramipril) confers significant protection against chemotherapy and combined modality therapy-induced cardiac dysfunction, including preservation of right ventricular function.
However, data from the Herceptin Adjuvant (HERA) trial (Int J Radiat Oncol Biol Phys, 2022; PMID 34986381) suggest that with contemporary radiotherapy planning, trastuzumab-treated HER2-positive patients do not have an increased risk of radiation-related cardiotoxicity.
Expert Commentary
Accumulating evidence enriches our understanding of the pathophysiology of RIHD, with coronary arterial damage, especially to the LAD, playing a central role in ischemic heart disease post-radiotherapy. The study by Quirk et al. confirms that the maximum LAD dose is a superior metric predictive of long-term cardiac events over traditional mean heart dose metrics. This has direct implications for radiotherapy planning, promoting a shift toward LAD-sparing techniques and stringent dose constraints.
The challenges of cardiac substructure contouring due to cardiac motion necessitate advanced imaging methods and uniform delineation protocols to avoid underestimation of cardiac risks. Furthermore, emerging respiratory motion management techniques, including various DIBH implementations, can be optimized to minimize LAD exposure.
Despite advances, heterogeneity in cardiac event reporting and dosimetry standards limit cross-study comparisons. Additionally, subclinical cardiac injuries detected by strain imaging or biomarker alterations warrant longitudinal studies to clarify their prognostic significance and guide early cardioprotection. Multidisciplinary collaboration between radiation oncologists and cardio-oncologists is essential for personalized risk assessment and mitigation.
Conclusion
Heart-sparing breast radiotherapy reduces cardiac risk, yet focal irradiation of the LAD remains a critical determinant of long-term cardiotoxicity. Maximum LAD dose surpasses mean heart dose in predicting adverse cardiac outcomes, advocating for its routine assessment in treatment planning. Advances in radiotherapy delivery and motion management techniques facilitate LAD sparing without compromising oncologic control. Future research should prioritize robust LAD contouring standards, prospective validation of dose thresholds, incorporation of subclinical cardiac injury biomarkers, and targeted cardioprotective strategies. Ultimately, individualized radiation planning integrating anatomical, dosimetric, and clinical risk factors will optimize long-term cardiovascular health for breast cancer survivors.
References
- Quirk S et al. Cardiac Risk After Heart-Sparing Breast Radiotherapy. JAMA Oncol. 2026 Jul;PMID: 42390858.
- Zhang M et al. Cardiovascular morbidity and mortality after radiotherapy for breast cancer: a systematic review and meta-analysis. Heart. 2025 Dec;112(1):6-12. PMID: 40348406.
- Park H et al. Long-term risk of major cardiac events in breast cancer patients treated with IMRT and 3D-CRT: Secondary analysis of a randomized clinical trial. Int J Cancer. 2025 Oct;157(7):1395-1404. PMID: 40345828.
- Majety M et al. Cardiac MRI-based Subclinical Cardiac Dysfunction during 2 Years after Breast Cancer Irradiation: The MEDIRAD EARLY-HEART Study. Radiol Cardiothorac Imaging. 2025 Apr;7(2):e240231. PMID: 40178396.
- Cozzolino M et al. Effect of Cardioprotection on Right Ventricular Function in Breast Cancer Patients Receiving Potentially Cardiotoxic Therapy: A SAFE Trial Substudy. Echocardiography. 2025 Sep;42(9):e70291. PMID: 40965835.
- Barker M et al. Cardiotoxicity in HER-2-positive breast cancer patients treated with radiation therapy and trastuzumab: Analysis of the HERA trial. Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):135-142. PMID: 34986381.
- Liao Y et al. Cardiac Magnetic Resonance Imaging and Blood Biomarkers for Evaluation of Radiation-Induced Cardiotoxicity in Breast Cancer Patients: Results of a Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):417-425. PMID: 34509552.
- Matsuo R et al. Patient and treatment-related factors influencing dose to heart and substructures in left-sided breast cancer radiotherapy: A systematic review. Phys Med. 2024 Dec;128:104851. PMID: 39504787.
- Botella F et al. Cardiac dose comparison of abdominal and thoracic deep inspiration breath hold in left-sided breast cancer radiation therapy: A systematic review and meta-analysis. Radiography (Lond). 2025 Jan;31(1):426-433. PMID: 39779416.
- Darby SC et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998. (Historical landmark study for comparison.)